We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in... Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California. Show more
Ask ADVFN Intelligence (AI)
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues focus on development of subcutaneous lonigutamab in...
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed and initiation...
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.075 | -2.38095238095 | 3.15 | 3.395 | 3.055 | 411569 | 3.23216458 | CS |
| 4 | -1.485 | -32.5657894737 | 4.56 | 4.87 | 3.055 | 821873 | 3.5704491 | CS |
| 12 | -1.875 | -37.8787878788 | 4.95 | 6.52 | 3.055 | 634278 | 4.72709446 | CS |
| 26 | -1.295 | -29.6338672769 | 4.37 | 7.25 | 3.055 | 868922 | 5.03833895 | CS |
| 52 | -4.385 | -58.7801608579 | 7.46 | 8.885 | 3.055 | 975349 | 5.77866055 | CS |
| 156 | -19.925 | -86.6304347826 | 23 | 29.88 | 3.055 | 1024635 | 9.7459716 | CS |
| 260 | -19.925 | -86.6304347826 | 23 | 29.88 | 3.055 | 1024635 | 9.7459716 | CS |
Monksdream
4 months ago
Monksdream
5 months ago
Monksdream
8 months ago
retireat40
1 year ago
makinezmoney
1 year ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
